WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011161970) ANTI-PDGF RECEPTOR ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/161970    International Application No.:    PCT/JP2011/003603
Publication Date: 29.12.2011 International Filing Date: 23.06.2011
IPC:
C07K 16/28 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01), C12N 1/15 (2006.01), C12N 1/19 (2006.01), C12N 1/21 (2006.01), C12N 5/10 (2006.01), C12N 15/09 (2006.01), C07K 14/705 (2006.01)
Applicants: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. [JP/JP]; 1091-1, Naka Aza-Higashida, Fujioka-shi, Gunma 3750005 (JP) (For All Designated States Except US).
SHIMIZU, Mamoru [JP/JP]; (JP) (For US Only).
MARUYAMA, Nobuhiro [JP/JP]; (JP) (For US Only).
HAMADA, Katsuyoshi [JP/JP]; (JP) (For US Only)
Inventors: SHIMIZU, Mamoru; (JP).
MARUYAMA, Nobuhiro; (JP).
HAMADA, Katsuyoshi; (JP)
Agent: HASEGAWA, Hiroshi; c/o HASEGAWA PATENT LAW FIRM, 2nd Floor Yokohama Yusen Building, 3-9, Kaigan-dori, Naka-ku, Yokohama-shi, Kanagawa 2310002 (JP)
Priority Data:
2010-143397 24.06.2010 JP
Title (EN) ANTI-PDGF RECEPTOR ANTIBODY
(FR) ANTICORPS ANTI-RÉCEPTEUR DE PDGF
(JA) 抗PDGF受容体抗体
Abstract: front page image
(EN)Disclosed are antibodies against PDGFRα and the use of same. Specifically disclosed are an anti-PDGFRα antibody that recognizes an amino acid sequence in an amino acid sequence from the 106th to the 311th position in a PDGFRα as an epitope, an anti-PDGRFα antibody that has 50% or greater antibody dependent cellular cytotoxicity (ADCC) activity in T cells, and an anti-PDGFRα antibody that has 15% or greater complement dependent cytotoxicity (CDC) activity. Also disclosed are the DNA that code the aforementioned antibodies and a pharmaceutical composition that includes the aforementioned antibodies as an effective component.
(FR)L'invention concerne des anticorps contre PDGFRα, et leur utilisation. L'invention concerne spécifiquement un anticorps anti-PDGFRα qui reconnaît une séquence d'acides aminés dans une séquence d'acides aminés de la 106e à la 311e position dans un PDGFRα en tant qu'épitope, un anticorps anti-PDGRFα qui présente une activité de cytotoxicité cellulaire dépendante des anticorps (ADCC) supérieure ou égale à 50 % dans des lymphocytes T, et un anticorps anti-PDGFRα qui présente une activité de cytotoxicité dépendante du complément (CDC) supérieure ou égale à 15 %. L'invention concerne également l'ADN qui code pour les anticorps susmentionnés et une composition pharmaceutique qui comprend les anticorps susmentionnés en tant que composant efficace.
(JA) 本発明はPDGFRαに対する抗体及びその利用を提供する。具体的には、本発明は、PDGFRαの106番目から311番目のアミノ酸配列に含まれるアミノ酸配列をエピトープとして認識する抗PDGFRα抗体、T細胞による抗体依存性細胞傷害性活性(ADCC活性)が50%以上である、抗PDGFRα抗体、補体依存性細胞傷害(CDC活性)が15%以上である、抗PDGFRα抗体等に関する。更に本発明は前記抗体をコードするDNA、及び前記抗体を有効成分として含有する医薬組成物に関する。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)